The lawsuit was filed by the pro-life Alliance for Hippocratic Medicine, which is being represented by Alliance Defending Freedom in court.
ADF Senior Counsel Erik Baptist said in a statement that the court’s decision follows common practice.
“As is common practice, the Supreme Court has decided to maintain the status quo that existed prior to our lawsuit while our challenge to the FDA’s illegal approval of chemical abortion drugs and its removal of critical safeguards for those drugs moves forward,” Baptist said.
“Our case seeking to put women’s health above politics continues on an expedited basis in the lower courts,” Baptist continued. “The FDA must answer for the damage it has caused to the health of countless women and girls and the rule of law by failing to study how dangerous the chemical abortion drug regimen is and unlawfully removing every meaningful safeguard, even allowing for mail-order abortions. We look forward to a final outcome in this case that will hold the FDA accountable.”
The U.S. Food and Drug Administration (FDA) approved mifepristone in 2000, but regulations have fluctuated since its approval. The current rules allow a person to receive the drug in person or through the mail and does not require the woman to be seen by a doctor in person before receiving it.
Alliance for Hippocratic Medicine filed a lawsuit, which argues that the original FDA approval and its subsequent regulatory changes did not follow legally required protocol. The lawsuit asks the court to declare the original approval of the drug and subsequent regulatory changes to increase access to the drug unlawful.
Credit: Source link
